Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer

Endocrine-Related Cancer

Volumn 21, Issue 4, 2014, Pages

  Ware, Kathryn E ^a   Garcia Blanco, Mariano A ^a   Armstrong, Andrew J ^a   Dehm, Scott M ^b,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Androgen receptor; AR variants; Castration resistant prostate cancer; Epithelial to mesenchymal transition; Metastasis; Splice variants

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; ENZALUTAMIDE; AR PROTEIN, HUMAN; TUMOR MARKER;

ALTERNATIVE RNA SPLICING; ANDROGEN DEPRIVATION THERAPY; CANCER CELL; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RECURRENCE; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL SUBPOPULATION; DNA BINDING; EPITHELIAL MESENCHYMAL TRANSITION; EXON; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC VARIABILITY; HINGE REGION; HORMONAL REGULATION; HUMAN; LIGAND BINDING; NEGATIVE FEEDBACK; NONHUMAN; NONSENSE MUTATION; OPEN READING FRAME; OVERALL SURVIVAL; POINT MUTATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION ELONGATION; TRANSCRIPTION INITIATION; ANIMAL; DISEASE COURSE; GENETIC VARIATION; GENETICS; MALE; METABOLISM;

ANIMALS; BIOMARKERS, TUMOR; DISEASE PROGRESSION; GENETIC VARIATION; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN;

EID: 84905974623     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0470     Document Type: Review

References (98)

1. Ahrens-Fath I, Politz O, Geserick C & Haendler B 2005 Androgen receptor function is modulated by the tissue-specific AR45 variant. FEBS Journal 272 74-84. (doi:10.1111/j.1432-1033.2004.04395.x)
2. Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, Watt K, Tam T, Yang YC, Banuelos CA et al. 2010 Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17 535-546. (doi:10.1016/j.ccr.2010.04.027)
3. Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, Herold CI, Marcom PK, George DJ & Garcia-Blanco MA 2011 Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Molecular Cancer Research 9 997-1007. (doi:10.1158/1541-7786.MCR-10-0490)
4. Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y & Sawyers CL 2013 Overcoming mutation-based resistance to antiandrogens with rational drug design. eLife 2 e00499. (doi:10.7554/eLife. 00499)
5. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST et al. 2011 Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discovery 1 487-495. (doi:10.1158/2159-8290.CD-11-0130)
6. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C et al. 2011 The genomic complexity of primary human prostate cancer. Nature 470 214-220. (doi:10.1038/nature09744)
7. Bergerat JP & Ceraline J 2009 Pleiotropic functional properties of androgen receptor mutants in prostate cancer. Human Mutation 30 145-157. (doi:10.1002/humu.20848)
8. Bitting RL, Schaeffer D, Somarelli JA, Garcia-Blanco MA & Armstrong AJ 2014 The role of epithelial plasticity in prostate cancer dissemination and treatment resistance. Cancer Metastasis Reviews.
9. Bohrer LR, Liu P, Zhong J, Pan Y, Angstman J, Brand LJ, Dehm SM & Huang H 2013 FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants. Prostate 73 1017-1027. (doi:10.1002/pros. 22649)
10. deBono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F et al. 2011 Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine 364 1995-2005. (doi:10.1056/NEJMoa1014618)
11. Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, Chen S, Nelson PS, Liu XS, Brown M et al. 2011 Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 20 457-471. (doi:10.1016/j.ccr.2011. 09.001)
12. Ceraline J, Erdmann E, Erbs P, Deslandres-Cruchant M, Jacqmin D, Duclos B, Klein-Soyer C, Dufour P & Bergerat JP 2003 A yeast-based functional assay for the detection of the mutant androgen receptor in prostate cancer. European Journal of Endocrinology 148 99-110. (doi:10.1530/eje.0.1480099)
13. Chan SC, Li Y & Dehm SM 2012 Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. Journal of Biological Chemistry 287 19736-19749. (doi:10.1074/jbc.M112. 352930)
14. Chang KH, Li R, Kuri B, Lotan Y, Roehrborn CG, Liu J, Vessella R, Nelson PS, Kapur P, Guo X et al. 2013 A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 154 1074-1084. (doi:10.1016/j.cell. 2013.07.029)
15. Chen H, Pong RC, Wang Z & Hsieh JT 2002 Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia: cloning and characterization. Genomics 79 573-581. (doi:10.1006/geno.2002.6739)
16. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG & Sawyers CL 2004 Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 10 33-39. (doi:10.1038/nm972)
17. Chen Y, Chi P, Rockowitz S, Iaquinta PJ, Shamu T, Shukla S, Gao D, Sirota I, Carver BS, Wongvipat J et al. 2013 ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nature Medicine 19 1023-1029. (doi:10.1038/nm.3216)
18. Choi N, Zhang B, Zhang L, Ittmann M & Xin L 2012 Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell 21 253-265. (doi:10.1016/j.ccr.2012.01.005)
19. Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L et al. 2012 ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Research 72 1494-1503. (doi:10.1158/0008-5472. CAN-11-3948)
20. Coffey K & Robson CN 2012 Regulation of the androgen receptor by posttranslational modifications. Journal of Endocrinology 215 221-237. (doi:10.1530/JOE-12-0238)
21. Cottard F, Asmane I, Erdmann E, Bergerat JP, Kurtz JE & Ceraline J 2013 Constitutively active androgen receptor variants upregulate expression of mesenchymal markers in prostate cancer cells. PLoS ONE 8 e63466. (doi:10.1371/journal.pone.0063466)
22. Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, Gjyrezi A, Chanel-Vos C, Shen R, Tagawa ST et al. 2011 Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Research 71 6019-6029. (doi:10.1158/0008- 5472.CAN-11-1417)
23. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL & Tindall DJ 2008 Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Research 68 5469-5477. (doi:10.1158/0008-5472.CAN-08-0594)
24. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC & Partin AW 2007 Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-causemortality. Journal of Clinical Oncology 25 1765-1771. (doi:10.1200/JCO.2006.08.0572)
25. Garraway LA & Sellers WR 2006 Lineage dependency and lineage-survival oncogenes in human cancer. Nature Reviews. Cancer 6 593-602. (doi:10.1038/nrc1947)
26. Ghigna C, Giordano S, Shen H, Benvenuto F, Castiglioni F, Comoglio PM, Green MR, Riva S & Biamonti G 2005 Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Molecular Cell 20 881-890. (doi:10.1016/j.molcel.2005.10.026)
27. Gillis JL, Selth LA, Centenera MM, Townley SL, Sun S, Plymate SR, Tilley WD & Butler LM 2013 Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. Oncotarget 4 691-704.
28. Goldstein AS, Huang J, Guo C, Garraway IP & Witte ON 2010 Identification of a cell of origin for human prostate cancer. Science 329 568-571. (doi:10.1126/science.1189992)
29. Gu W, Zhang F & Lupski JR 2008 Mechanisms for human genomic rearrangements. PathoGenetics 1 4. (doi:10.1186/1755-8417-1-4)
30. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ et al. 2009 A novel androgen receptor splice variant is upregulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Research 69 2305-2313. (doi:10.1158/0008-5472.CAN-08-3795)
31. Gurusamy D, Gray JK, Pathrose P, Kulkarni RM, Finkleman FD & Waltz SE 2013 Myeloid-specific expression of Ron receptor kinase promotes prostate tumor growth. Cancer Research 73 1752-1763. (doi:10.1158/0008-5472.CAN-12-2474)
32. Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J et al. 2010 Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nature Genetics 42 668-675. (doi:10.1038/ng.613)
33. Han G, Foster BA, Mistry S, Buchanan G, Harris JM, Tilley WD & Greenberg NM 2001 Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. Journal of Biological Chemistry 276 11204-11213. (doi:10.1074/jbc.M008207200)
34. Hastings PJ, Ira G & Lupski JR 2009 A microhomology-mediated break-induced replication model for the origin of human copy number variation. PLoS Genetics 5 e1000327. (doi:10.1371/journal.pgen.1000327)
35. Hornberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, Bergh A & Wikstrom P 2011 Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS ONE 6 e19059. (doi:10.1371/journal.pone.0019059)
36. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB et al. 2009 Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Research 69 16-22. (doi:10.1158/0008-5472.CAN-08-2764)
37. Hu R, Isaacs WB & Luo J 2011 A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate 71 1656-1667. (doi:10.1002/pros.21382)
38. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E et al. 2012 Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Research 72 3457-3462. (doi:10.1158/0008-5472.CAN-11-3892)
39. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B et al. 2006 Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). Journal of Clinical Oncology 24 3984-3990. (doi:10.1200/JCO.2006.06.4246)
40. Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, Moon M, Maneval EC, Chen I, Darimont B et al. 2013 A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discovery 3 1020-1029. (doi:10.1158/2159-8290. CD-13-0226)
41. Joung JK & Sander JD 2013 TALENs: a widely applicable technology for targeted genome editing. Nature Reviews. Molecular Cell Biology 14 49-55. (doi:10.1038/nrm3486)
42. Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, Yuan J, Kovats SG, Kim S, Cooke VG et al. 2013 An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (Enzalutamide). Cancer Discovery 3 1030-1043. (doi:10.1158/2159-8290.CD-13-0142)
43. Koumbaris G, Hatzisevastou-Loukidou H, Alexandrou A, Ioannides M, Christodoulou C, Fitzgerald T, Rajan D, Clayton S, Kitsiou-Tzeli S, Vermeesch JR et al. 2011 FoSTeS, MMBIR and NAHR at the human proximal Xp region and themechanisms of human Xq isochromosome formation. Human Molecular Genetics 20 1925-1936. (doi:10.1093/hmg/ddr074)
44. Lai KP, Huang CK, Chang YJ, Chung CY, Yamashita S, Li L, Lee SO, Yeh S & Chang C 2013 New therapeutic approach to suppress castrationresistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. American Journal of Pathology 182 460-473. (doi:10.1016/j. ajpath.2012.10.029)
45. Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH & Dehm SM 2011 Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Research 71 2108-2117. (doi:10.1158/0008-5472.CAN-10-1998)
46. Li Y, Hwang TH, Oseth LA, Hauge A, Vessella RL, Schmechel SC, Hirsch B, Beckman KB, Silverstein KA & Dehm SM 2012 AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene 31 4759-4767. (doi:10.1038/onc.2011.637)
47. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA & Dehm SM 2013 Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Research 73 483-489. (doi:10.1158/0008-5472.CAN-12-3630)
48. Libertini SJ, Tepper CG, Rodriguez V, Asmuth DM, Kung HJ & Mudryj M 2007 Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Research 67 9001-9005. (doi:10.1158/0008-5472. CAN-07-1072)
49. Lin C, Yang L, Tanasa B, Hutt K, Ju BG, Ohgi K, Zhang J, Rose DW, Fu XD, Glass CK et al. 2009 Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 139 1069-1083. (doi:10.1016/j.cell.2009.11.030)
50. Lin TH, Izumi K, Lee SO, Lin WJ, Yeh S & Chang C 2013 Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancermetastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death & Disease 4 e764. (doi:10.1038/cddis.2013.270)
51. Liu G, Sprenger C, Sun S, Epilepsia KS, Haugk K, Zhang X, Coleman I, Nelson PS & Plymate S 2013a AR variant AR(v567es) induces carcinogenesis in a novel transgenic mouse model of prostate cancer. Neoplasia 15 1009-1017.
52. Liu LL, Xie N, Sun S, Plymate S, Mostaghel E & Dong X 2013b Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene.
53. Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C, Albiges L, Attard G, Fizazi K, De Bono JS et al. 2013 Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Annals of Oncology 24 1807-1812. (doi:10.1093/annonc/mdt136)
54. Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S, Palanisamy N & Chinnaiyan AM 2009 Induced chromosomal proximity and gene fusions in prostate cancer. Science 326 1230. (doi:10.1126/science.1178124)
55. McGrath MJ, Binge LC, Sriratana A, Wang H, Robinson PA, Pook D, Fedele CG, Brown S, Dyson JM, Cottle DL et al. 2013 Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer. Cancer Research 73 5066-5079. (doi:10.1158/0008-5472.CAN-12-4520)
56. Mediwala SN, Sun H, Szafran AT, Hartig SM, Sonpavde G, Hayes TG, Thiagarajan P, Mancini MA & Marcelli M 2013 The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way. Prostate 73 267-277. (doi:10.1002/pros.22566)
57. Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, Guney I, Strochlic DE, Macconaill LE, Beroukhim R et al. 2010 An oncogenetumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB. Nature Medicine 16 286-294. (doi:10.1038/nm.2100)
58. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS & Montgomery RB 2011 Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clinical Cancer Research 17 5913-5925. (doi:10.1158/1078-0432.CCR-11-0728)
59. Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, Gleave M & Wu H 2012 Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Research 72 1878-1889. (doi:10.1158/0008-5472.CAN-11-3132)
60. Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, Yang YC, Tavakoli I, Haile S, Watt K et al. 2013 An androgen receptor N-terminal domain antagonist for treating prostate cancer. Journal of Clinical Investigation 123 2948-2960. (doi:10.1172/JCI66398)
61. Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP & Gao AC 2013 NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Molecular Cancer Therapeutics 12 1629-1637. (doi:10.1158/1535-7163.MCT-13-0027)
62. Nakka M, Agoulnik IU & Weigel NL 2013 Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. International Journal of Biochemistry & Cell Biology 45 763-772. (doi:10.1016/j.biocel.2012.12.012)
63. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL & Chi KN 2013 Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Annals of Oncology 24 1802-1807. (doi:10.1093/annonc/mdt138)
64. Nyquist MD, Li Y, Hwang TH, Manlove LS, Vessella RL, Silverstein KA, Voytas DF & Dehm SM 2013 TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. PNAS 110 17492-17497.
65. O'Connell MP, Fiori JL, Baugher KM, Indig FE, French AD, Camilli TC, Frank BP, Earley R, Hoek KS, Hasskamp JH et al. 2009 Wnt5A activates the calpain-mediated cleavage of filamin A. Journal of Investigative Dermatology 129 1782-1789. (doi:10.1038/jid.2008.433)
66. Oh SJ, Erb HH, Hobisch A, Santer FR & Culig Z 2012 Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. Endocrine-Related Cancer 19 305-319. (doi:10.1530/ERC-11-0298)
67. Rios-Doria J, Kuefer R, Ethier SP & Day ML 2004 Cleavage of b-catenin by calpain in prostate and mammary tumor cells. Cancer Research 64 7237-7240. (doi:10.1158/0008-5472.CAN-04-1048)
68. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S et al. 2013 Abiraterone in metastatic prostate cancer without previous chemotherapy. New England Journal of Medicine 368 138-148. (doi:10.1056/NEJMoa1209096)
69. Schaeffer AJ 2013 Editorial comment. Urology 81 555-556 discussion 556. (doi:10.1016/j.urology.2012.10.062)
70. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J et al. 2010 Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375 1437-1446. (doi:10.1016/S0140-6736(10)60172-9)
71. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND et al. 2012 Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine 367 1187-1197. (doi:10.1056/NEJMoa1207506)
72. Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, Liu F, Planck JL, Ravindranathan P, Chinnaiyan AM et al. 2012 Dual roles of PARP-1 promote cancer growth and progression. Cancer Discovery 2 1134-1149. (doi:10.1158/2159-8290.CD-12-0120)
73. Shafi AA, Cox MB & Weigel NL 2013 Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression. Steroids 78 548-554. (doi:10.1016/j.steroids.2012.12. 013)
74. Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, Thangavel C, Morrissey C, Zhang X, Comstock CE, Witkiewicz AK et al. 2010 The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. Journal of Clinical Investigation 120 4478-4492. (doi:10.1172/JCI44239)
75. Shiota M, Yokomizo A, Fujimoto N & Naito S 2011 Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castration-resistant prostate cancer. Current Cancer Drug Targets 11 870-881. (doi:10.2174/156800911796798904)
76. Siegel RD 2013 American Society of Clinical Oncology Quality Care Symposium 2012: re-engineeringyourpractice todeliverquality andvalue. Journal of Oncology Practice 9 160-161. (doi:10.1200/JOP.2013.000925)
77. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG & Balk SP 2006 Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Research 66 2815-2825. (doi:10.1158/0008-5472.CAN-05-4000)
78. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H et al. 2010 Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. Journal of Clinical Investigation 120 2715-2730. (doi:10.1172/JCI41824)
79. Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ et al. 2012 Androgen deprivation causes epithelial- mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Research 72 527-536. (doi:10.1158/0008-5472.CAN-11-3004)
80. Sun F, Chen HG, Li W, Yang X, Wang X, Jiang R, Guo Z, Chen H, Huang J, Borowsky AD et al. 2013 Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/ paracrine factors. Journal of Biological Chemistry 289 1529-1539. (doi:10.1074/jbc.M113.492140)
81. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL et al. 2010 Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nature Medicine 16 1414-1420. (doi:10.1038/nm.2236)
82. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B et al. 2010 Integrative genomic profiling of human prostate cancer. Cancer Cell 18 11-22. (doi:10.1016/j.ccr.2010.05.026)
83. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG & Kung HJ 2002 Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Research 62 6606-6614. (Pubitemid 35364127)
84. Thadani-Mulero M, Nanus DM & Giannakakou P 2012 Androgen receptor on the move: boarding the microtubule expressway to the nucleus. Cancer Research 72 4611-4615. (doi:10.1158/0008-5472.CAN-12-0783)
85. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A et al. 2009 Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324 787-790. (doi:10.1126/science.1168175)
86. Tsai HC, Boucher DL, Martinez A, Tepper CG & Kung HJ 2012 Modeling truncated AR expression in a natural androgen responsive environment and identification of RHOB as a direct transcriptional target. PLoS ONE 7 e49887. (doi:10.1371/journal.pone.0049887)
87. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, Hu YP, Price SM, Abate-Shen C & Shen MM 2009 A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461 495-500. (doi:10.1038/nature08361)
88. Wang ZA, Mitrofanova A, Bergren SK, Abate-Shen C, Cardiff RD, Califano A & Shen MM 2013 Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-originmodel for prostate cancer heterogeneity. Nature Cell Biology 15 274-283. (doi:10.1038/ncb2697)
89. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K & Sawyers CL 2010 Constitutively active androgen receptor splice variants expressedincastration-resistantprostate cancer require full-length-androgen receptor. PNAS 107 16759-16765. (doi:10.1073/pnas.1012443107)
90. Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H, Rausch T et al. 2013 Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 23 159-170. (doi:10.1016/j.ccr.2013.01.002)
91. van de Wijngaart DJ, Dubbink HJ, van Royen ME, Trapman J & Jenster G 2012 Androgen receptor coregulators: recruitment via the coactivator binding groove. Molecular and Cellular Endocrinology 352 57-69. (doi:10.1016/j.mce.2011. 08.007)
92. Wu K, Liu J, Tseng SF, Gore C, Ning Z, Sharifi N, Fazli L, Gleave M, Kapur P, Xiao G et al. 2013 The role of DAB2IP in androgen receptor activation during prostate cancer progression. Oncogene.
93. Xu K, Wu ZJ, Groner AC, HeHH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T et al. 2012 EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 338 1465-1469. (doi:10.1126/science. 1227604)
94. Yamashita S, Lai KP, Chuang KL, Xu D, Miyamoto H, Tochigi T, Pang ST, Li L, Arai Y, Kung HJ et al. 2012 ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia 14 74-83.
95. Yang X, Guo Z, Sun F, Li W, Alfano A, Shimelis H, Chen M, Brodie AM, Chen H, Xiao Z et al. 2011 Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells. Journal of Biological Chemistry 286 36152-36160. (doi:10.1074/jbc.M111. 265124)
96. Zengerling F, Streicher W, Schrader AJ, Schrader M, Nitzsche B, Cronauer MV & Hopfner M 2012 Effects of sorafenib on C-terminally truncated androgen receptor variants in human prostate cancer cells. International Journal of Molecular Sciences 13 11530-11542. (doi:10.3390/ijms130911530)
97. Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, Vakar-Lopez F, Vessella RL & Plymate SR 2011 Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS ONE 6 e27970. (doi:10.1371/journal.pone.0027970)
98. Zhao H, Coram MA, Nolley R, Reese SW, Young SR & Peehl DM 2012 Transcript levels of androgen receptor variant AR-V1 or AR-V7 do not predict recurrence in patients with prostate cancer at indeterminate risk for progression. Journal of Urology 188 2158-2164. (doi:10.1016/j.juro.2012.08.014)